In this video, I break down whether Eli Lilly stock is still a strong buy in 2026 after an explosive year of growth. I will walk you through the company’s latest earnings report, revenue guidance, blockbuster obesity drugs like Mounjaro and Zepbound, and its powerful pipeline including orforglipron and retatrutide. With shares trading around $1,038 and analysts projecting major upside, I will analyze whether the valuation still makes sense and what could drive the next big move. Eli Lilly just delivered 45% revenue growth in 2025 and guided for up to $83 billion in revenue for 2026. The real question is what happens next. I will break down the catalysts that could push this stock significantly higher, including global expansion, new drug approvals, and strategic acquisitions like Orna Therapeutics. In this video, you’ll learn: How Lilly grew revenue from $45B to $65B in one year Why Mounjaro and Zepbound are reshaping the obesity market What Phase 3 results really mean for orforglipron and retatrutide Whether 30x forward earnings is justified The realistic path to $1,500 per share If you are looking for a high-quality, defensive compounder with massive growth catalysts, this is a stock you need to understand. Skip ahead: 0:00 - Intro 1:44 - Eli Lilly's overview 2:46 - LLY's price 3:22 - Financials 4:28 - Growth catalysts 7:12 - Valuation 8:44 - Verdict #EliLilly #LLY #LLYStock #PharmaStocks #HealthcareStocks #WeightLossStocks #ObesityDrugs #Mounjaro #Zepbound #DividendStocks #GrowthStocks #StockMarket2026 #Investing #LongTermInvesting #rickorford Grab Your 10 Stock Picks From Stock Advisor: https://fool.com/ricko Discord: https://rickorford.com/join Website: https://rickorford.com Try Barchart's Free Stock Screener: https://rickorford.com/barchart-stocks Don’t forget to like, subscribe, and turn on notifications for more exclusive content! DISCLAIMER: Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 17, 2026. A portion of this video is sponsored by The Motley Fool. Visit https://fool.com/ricko to get access to my special offer. The Motley Fool Stock Advisor returns are 981% as of 12/10/2025 and measured against the S&P 500 returns of 194% as of 12/10/2025. Dividend Aristocrats® is a registered trademark of Standard & Poor's Financial Services LLC. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video. This video is for educational purposes only and not financial advice. Always do your own research and consult with a financial advisor before making any investment decisions. All information and data on this YouTube Channel is solely for entertainment purposes. I'm not a financial advisor, nor licensed in any way to provide any financial advice. The information herein is based solely on my personal opinion and experience. All investments hold inherent risk, and the information provided on this YouTube Channel should not be interpreted as any kind of guidance, recommendation, offer, advice, or suggestion. Any ideas and strategies discussed on this channel should not be implemented without first considering your financial and personal circumstances or without consulting a financial professional.